Type 2 Diabetes Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The type 2 diabetes market size has grown strongly in recent years. It will grow from $48.14 billion in 2024 to $51.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to lifestyle and dietary changes, aging population, pharmaceutical developments, public health initiatives.

The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $72.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to global diabetes epidemic, personalized medicine, technological advancements, healthcare policy changes. Major trends in the forecast period include digital health and telemedicine, prevention and early intervention, artificial intelligence (AI) and machine learning (ML), metabolic surgery.

The increasing prevalence of obesity and heart disease is expected to drive the growth of the type 2 diabetes market in the coming years. Obesity is a condition characterized by excessive body fat accumulation, while heart disease encompasses a variety of conditions affecting the heart and blood vessels. Excess weight increases the risk of insulin resistance, leading to elevated blood sugar levels and the development of type 2 diabetes. Conversely, high blood sugar can damage blood vessels and nerves, contributing to heart disease. For instance, in March 2024, the World Health Organization (WHO) reported that approximately one in eight people globally are affected by obesity. This includes 2.5 billion adults (aged 18 and older) who are overweight, with 890 million living with obesity. Among adults, 43% are overweight and 16% are obese. Additionally, 37 million children under five years old are overweight. As such, the rising rates of obesity and heart disease are fueling the growth of the type 2 diabetes market.

The rising geriatric population is expected to significantly propel the growth of the type 2 diabetes market in the coming years. The geriatric population, defined as individuals aged 65 years and older, is particularly vulnerable to various health issues due to reduced immunity and age-related factors. As people age, they are at increased risk for Type 2 diabetes-related complications such as hypoglycemia (low blood sugar), renal failure, and cardiovascular diseases, all of which can lead to both acute and chronic microvascular and cardiovascular problems. For example, in July 2023, the World Health Organization (WHO) projected that by 2030, 1 in 6 people worldwide will be aged 60 or older. Additionally, the global population of individuals aged 60 and above is expected to double to 2.1 billion by 2050, with a significant increase in the number of people aged 80 or older. Given these trends, the growing geriatric population is driving the demand for treatments and management solutions in the type 2 diabetes market.

Prominent companies operating in the type 2 diabetes market are pioneering innovative products such as Mounjaro to elevate the standards of safety and effectiveness in diabetic patient care. Innovative medications like Mounjaro aim to enhance the efficiency, safety, or convenience of diabetes management when compared to existing drugs. Advancements in the development of diabetes treatments focus on optimizing blood sugar regulation, minimizing adverse effects, and addressing other associated health issues. For instance, in May 2022, Eli Lilly and Co., a US-based pharmaceutical firm, secured approval from the U.S. Food and Drug Administration, a US-based government body, for Mounjaro (tripeptide) injection as an adjunct to diet and exercise for improving blood sugar control in adults with type 2 diabetes. Tirzepatide, a novel, dual-targeted therapy for type 2 diabetes, is delivered as a once-weekly injection, simultaneously targeting two hormones involved in blood sugar regulation, namely glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 contributes to increased insulin production and reduced glucagon production, while GIP stimulates insulin production. Tirzepatide stands as a promising novel treatment option for individuals with type 2 diabetes, including those who have responded poorly to other treatments.

In January 2024, Roche Group, a Switzerland-based healthcare company, acquired Carmot Therapeutics for an undisclosed amount. This acquisition allows Roche to gain access to Carmot's current R&D portfolio, including both clinical and pre-clinical assets, as well as exclusive rights to Carmot's innovative Chemotype Evolution discovery platform. This platform, which focuses on metabolism, will significantly enhance Roche’s research and development capabilities in the fields of cardiovascular and metabolic diseases. Carmot Therapeutics, a clinical-stage biotechnology company, specializes in advancing therapeutics aimed at treating obesity and diabetes, and the acquisition aligns with Roche’s strategy to expand its portfolio in metabolic disease treatments.

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.

North America was the largest region in the type 2 diabetes market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the type 2 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Type 2 diabetes is a persistent metabolic disorder characterized by elevated blood sugar levels attributed to insulin resistance and insufficient insulin production. The development of Type 2 diabetes is the result of a combination of genetic, lifestyle, and environmental factors. Effective management of type 2 diabetes can be achieved through dietary modifications, pharmaceutical interventions that aid in weight reduction, adherence to a healthy diet, and consistent physical activity.

In the realm of type 2 diabetes management, various classes of drugs are available, including dipeptidyl peptide-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, other insulin secretagogues, biguanides, sodium-glucose cotransporter 2 inhibitors, and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral medications designed to impede the action of the enzyme responsible for breaking down incretin hormones, which play a crucial role in regulating blood sugar levels. These drugs find applications in diverse areas, including glycemic control, cardiovascular safety, prevention of hypoglycemia, and more, catering to various age groups, including children and adults.

The type 2 diabetes market research report is one of a series of new reports that provides type 2 diabetes market statistics, including type 2 diabetes industry global market size, regional shares, competitors with a type 2 diabetes market share, detailed type 2 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 2 diabetes industry. This type 2 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.